Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 120}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-07-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-05', 'completionDateStruct': {'date': '2018-07-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-05-08', 'studyFirstSubmitDate': '2022-02-14', 'studyFirstSubmitQcDate': '2022-05-04', 'lastUpdatePostDateStruct': {'date': '2022-05-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-05-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-07-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'PaO2', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'Arterial partial pressure of oxygen'}, {'measure': 'PaO2', 'timeFrame': 'change from baseline to 4 hours', 'description': 'Arterial partial pressure of oxygen'}, {'measure': 'PaO2', 'timeFrame': 'change from baseline to 8 hours', 'description': 'Arterial partial pressure of oxygen'}, {'measure': 'SaO2', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'arterial oxygen saturation'}, {'measure': 'SaO2', 'timeFrame': 'change from baseline to 4 hours', 'description': 'arterial oxygen saturation'}, {'measure': 'SaO2', 'timeFrame': 'change from baseline to 8 hours', 'description': 'arterial oxygen saturation'}, {'measure': 'PaO2/FiO2', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen'}, {'measure': 'PaO2/FiO2', 'timeFrame': 'change from baseline to 4 hours', 'description': 'oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen'}, {'measure': 'PaO2/FiO2', 'timeFrame': 'change from baseline to 8 hours', 'description': 'oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen'}], 'secondaryOutcomes': [{'measure': 'PaCO2', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'arterial partial pressure of carbon dioxide'}, {'measure': 'PaCO2', 'timeFrame': 'change from baseline to 4 hours', 'description': 'arterial partial pressure of carbon dioxide'}, {'measure': 'PaCO2', 'timeFrame': 'change from baseline to 8 hours', 'description': 'arterial partial pressure of carbon dioxide'}, {'measure': 'SpO2', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'blood oxygen saturation'}, {'measure': 'SpO2', 'timeFrame': 'change from baseline to 4 hours', 'description': 'blood oxygen saturation'}, {'measure': 'SpO2', 'timeFrame': 'change from baseline to 8 hours', 'description': 'blood oxygen saturation'}, {'measure': 'heart rate', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'heart rate'}, {'measure': 'heart rate', 'timeFrame': 'change from baseline to 4 hours', 'description': 'heart rate'}, {'measure': 'heart rate', 'timeFrame': 'change from baseline to 8 hours', 'description': 'heart rate'}, {'measure': 'inspired oxygen', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'percent fraction inspired oxygen'}, {'measure': 'inspired oxygen', 'timeFrame': 'change from baseline to 4 hours', 'description': 'percent fraction inspired oxygen'}, {'measure': 'inspired oxygen', 'timeFrame': 'change from baseline to 8 hours', 'description': 'percent fraction inspired oxygen'}, {'measure': 'ventilator tidal volume', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'tidal volume in ml'}, {'measure': 'ventilator tidal volume', 'timeFrame': 'change from baseline to 4 hours', 'description': 'tidal volume in ml'}, {'measure': 'ventilator tidal volume', 'timeFrame': 'change from baseline to 8 hours', 'description': 'tidal volume in ml'}, {'measure': 'ventilator peak inspiratory pressure', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'peak airway pressure in CMH2O'}, {'measure': 'ventilator peak inspiratory pressure', 'timeFrame': 'change from baseline to 4 hours', 'description': 'peak airway pressure in CMH2O'}, {'measure': 'ventilator peak inspiratory pressure', 'timeFrame': 'change from baseline to 8 hours', 'description': 'peak airway pressure in CMH2O'}, {'measure': 'ventilator peak airway plateau pressure', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'airway plateau pressure in CMH2O'}, {'measure': 'ventilator peak airway plateau pressure', 'timeFrame': 'change from baseline to 4 hours', 'description': 'airway plateau pressure in CMH2O'}, {'measure': 'ventilator peak airway plateau pressure', 'timeFrame': 'change from baseline to 8 hours', 'description': 'airway plateau pressure in CMH2O'}, {'measure': 'ventilator peak end expiratory pressure', 'timeFrame': 'change from baseline to 5 minutes', 'description': 'airway end expiratory pressure in CMH2O'}, {'measure': 'ventilator peak end expiratory pressure', 'timeFrame': 'change from baseline to 4 hours', 'description': 'airway end expiratory pressure in CMH2O'}, {'measure': 'ventilator peak end expiratory pressure', 'timeFrame': 'change from baseline to 8 hours', 'description': 'airway end expiratory pressure in CMH2O'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Ventilation Therapy; Complications', 'Airway Clearance Impairment']}, 'descriptionModule': {'briefSummary': 'Catheter suction (CS), the standard method for airway secretion management during mechanical ventilation, is invasive and has significant hemodynamic and traumatic side effects. In-line mechanical insufflation-exsufflation (IL-MIE) is a new, noninvasive technology that clears secretions by cough-simulation, without interrupting ongoing ventilation. It is not known whether IL-MIE can be safely and effectively used as an alternative to CS in ventilated patients. Methods: A randomized, controlled, non-inferiority study comparing a standard protocol of CS, with automatic IL-MIE (CoughSync, Ruxin Medical Systems, Beijing) performed every 30 minutes, with CS added only if needed, in post-operative ventilated patients.', 'detailedDescription': "The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial. The study was carried out in two Intensive Care Units - the Cardiac Surgery ICU at Anzhen Hospital, and the Critical Care Medicine ICU at Tian Tan Hospital - both in Beijing, China, over a 36 month period between July 2015 and July 2018. The study group included patients aged 18 to 75 years undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure.\n\nSubjects were randomized to either a control group, managed for 8 hours with CS whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's, or a study group, managed for 8 hours with automatic IL-MIE treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with CS performed only if signs of airway secretion accumulation manifested despite ongoing IL-MIE. IL-MIE was performed using standard IL-MIE parameters (exsufflation pressure = -60 cm H2O, with flutter, 10 coughs/treatment).\n\nBefore each CS treatment, 100% oxygen was administered for one minute, regardless of the patient's baseline oxygen requirement, as per standard operating protocol in that ICU. Before IL-MIE treatments, no additional oxygen was administered beyond the patient's baseline oxygen requirement.\n\nPharmacological management in both groups included analgesia and sedation as routinely used postoperatively in those ICU's.\n\nDemographic information and vital signs were recorded for all subjects. Arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2 ) and oxygenation index (PaO2/FiO2) were defined as the primary end points of the study, and arterial partial pressure of carbon dioxide (PaCO2), pulseoximetry (SpO2), heart rate (HR), and ventilator parameters (inspired oxygen, tidal volume \\[Vt\\], peak inspiratory pressure \\[PIP\\], airway plateau pressure \\[Pplat\\], and PEEP) as secondary end points.\n\nAll primary and secondary end-point data were recorded at baseline (2 minutes prior to starting the trial), and at 5 minutes, 4 hours and 8 hours after commencement of the trial. The number of CS treatments performed on each subject was recorded throughout the trial. Follow up for adverse events was performed during, and 48 hours after completion of, the trial.\n\nStatistical Analysis:\n\nThe minimum sample size required to demonstrate non-inferiority, was calculated to be 49 in each cohort, or a total of 98 subjects in total.\n\nCollected data were analyzed with a mixed model with repeated measures (MMRM) considering all observations (2 minutes before commencement of the trial protocol, and at 5 minutes, 4 hours and 8 hours thereafter) and accounting for the baseline value of oxygenation. For the indices of oxygenation derived from blood gas measurements (PaO2, SaO2 , and oxygenation index), non-inferiority was evaluated by comparison to the two-sided 95% confidence interval of the treatment effect in the MMRM model, with non-inferiority between the IL-MIE and control cohorts established if the lower limit of the 95% confidence interval for the intergroup difference in least squares mean for a measured index was found to be higher than the pre-determined non-inferiority margin for that index. For comparison of other quantitative data between groups, a two-sample t-test or Wilcoxon rank sum test was used, based on the data distribution. For between-group comparison of subjects with significant adverse events, a chi-square test was used. The number of CS treatments performed in each cohort was analyzed post-hoc as an exploratory analysis."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* patients undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure\n* Ventilation expected to last more than 8 hours\n\nExclusion Criteria:\n\n* acute spinal cord shock\n* recent airway trauma or surgery\n* cardiogenic pulmonary edema or ARDS necessitating ventilation with a peak end expiratory pressure (PEEP) equal to or greater than 6 cmH2O\n* pneumothorax\n* hemoptysis\n* severe ischemic heart disease\n* lung tumors\n* pulmonary Tuberculosis\n* history of lung transplantation\n* pregnant or breastfeeding women'}, 'identificationModule': {'nctId': 'NCT05365620', 'briefTitle': 'In-line Mechanical Insufflation-Exsufflation in the Management of Ventilated Patients', 'organization': {'class': 'OTHER', 'fullName': 'Alyn Pediatric & Adolescent Rehabilitation Hospital'}, 'officialTitle': 'In-line Mechanical Insufflation-Exsufflation as an Alternative to Invasive Suction for Secretion Management in Ventilated Patients', 'orgStudyIdInfo': {'id': '047-21'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Catheter Suction', 'description': "Patients in this arm were managed for 8 hours with Catheter Suction whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's", 'interventionNames': ['Procedure: catheter suction']}, {'type': 'EXPERIMENTAL', 'label': 'Mechanical Inexsufflation', 'description': 'Patients in this are were managed for 8 hours with automatic inexsufflation treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with Catheter Suction performed only if signs of airway secretion accumulation manifested', 'interventionNames': ['Device: Mechanical In-Line Inexsufflation']}], 'interventions': [{'name': 'Mechanical In-Line Inexsufflation', 'type': 'DEVICE', 'description': "In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.", 'armGroupLabels': ['Mechanical Inexsufflation']}, {'name': 'catheter suction', 'type': 'PROCEDURE', 'description': 'catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.', 'armGroupLabels': ['Catheter Suction']}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Alyn Pediatric & Adolescent Rehabilitation Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Beijing Anzhen Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director of Department of Respiratory Rehabilitation', 'investigatorFullName': "Eliezer be'eri", 'investigatorAffiliation': 'Alyn Pediatric & Adolescent Rehabilitation Hospital'}}}}